Most therapies in development for Alzheimer’s are focused on changing disease biology, with targets ranging from amyloid pathology to inflammation. A leader of our clinical trials program shares an update on drug development and diagnostics.
This risk gene increases the odds that initial symptoms will involve memory in patients with Alzheimer’s but not in those with Lewy body disease. So finds a large cohort study with implications for targeted therapeutics.
For the first time, this imaging tracer will be used in an attempt to detect neuroinflammation in the living brain in the setting of Parkinson’s and Alzheimer’s diseases.
Learn why this distinguished clinician-researcher expects to accomplish in one year here what would have taken 10 years at another institution.
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services Policy
Will we fight neurodegenerative diseases the way we robustly took on HIV/AIDS — or with the limited attention we’ve devoted to combating malaria?
A large NIH grant has helped form the first national research consortium for this common neurodegenerative dementia. The search for biomarkers is high on its to-do list.